Circulating tumor cells as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease.

被引：0
|
作者：
Raut, Nirmal Vivek
Bharde, Atul
Gourishankar, Aland
Jayant, Sreeja
Garbhe, Meghana
Gosavi, Sayali
Janorkar, Apoorva
D'Souza, Alain
Vasudevan, Aravindan
Khandare, Jayant
机构：
[1] Dr Vishwanath Karad World Peace Univ, Sch Consciousness, Pune, India
[2] Savitribai Phule Pune Univ, Pune, India
[3] Actorius Innovat & Res Pvt Ltd, Pune, India
[4] Actorius Res & Innovat, Pune, India
[5] Actorius Res & Innovat Co, Cupertino, CA USA
[6] Onecell Diag, Cupertino, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15021
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors
    Ardeshir-Larijani, Fatemeh
    Ravichandran, Karthik Raja
    Schneider, Bryan P.
    Radovich, Milan
    Maniar, Rohan
    Masood, Ashiq
    Kesler, Kenneth
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer
    Majure, Melanie
    Logan, Aaron C.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (24)
  • [33] ASO Visual Abstract: Optimizing Circulating Tumor DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma—Diagnosis, Screening, Minimal Residual Disease Detection, and Treatment Response Monitoring
    Woo Jin Choi
    Tommy Ivanics
    Annabel Gravely
    Steven Gallinger
    Gonzalo Sapisochin
    Grainne M. O’Kane
    Annals of Surgical Oncology, 2023, 30 : 3866 - 3867
  • [34] In Vivo Lymphatic Circulating Tumor Cells and Progression of Metastatic Disease
    Han, Mikyung
    Watts, Julia Alex
    Jamshidi-Parsian, Azemat
    Nadeem, Urooba
    Sarimollaoglu, Mustafa
    Siegel, Eric R.
    Zharov, Vladimir P.
    Galanzha, Ekaterina I.
    CANCERS, 2020, 12 (10) : 1 - 18
  • [35] Circulating Tumor DNA for Solid Tumor Minimal/ Molecular Residual Disease Detection in Cancer Survivors
    Sorscher, Steven
    AMERICAN JOURNAL OF MEDICINE, 2024, 137 (12): : 1168 - 1169
  • [36] CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA
    Liu, Anthony Pak-Yin
    Kumar, Rahul
    Kyle, Smith
    Paul, Leena
    Chintagumpala, Murali
    Bouffet, Eric
    Fisher, Michael J.
    Hassall, Tim
    Gururangan, Sri
    Hansford, Jordan
    Cohn, Richard
    Ellison, David W.
    Gilbertson, Richard J.
    Gajjar, Amar
    Robinson, Giles W.
    Northcott, Paul A.
    NEURO-ONCOLOGY, 2020, 22 : 401 - 402
  • [37] Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)
    Chen, Huijuan
    Zhou, Qiming
    ONCOLOGY REPORTS, 2023, 49 (05)
  • [38] Quantitative molecular monitoring of circulating lymphoma cells for the detection of minimal residual disease in follicular and mantle cell lymphoma
    Schüler, F
    Hirt, C
    Dölken, L
    Krüger, W
    Dölken, G
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2005, 130 (38) : 2130 - 2134
  • [39] Multifunctional Hybrid Nanozymes for Magnetic Enrichment and Bioelectrocatalytic Sensing of Circulating Tumor RNA during Minimal Residual Disease Monitoring
    Koo, Kevin M.
    CATALYSTS, 2023, 13 (01)
  • [40] Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancer
    Boysen, Anders K.
    Pallisgaard, Niels
    Andersen, Christina S. A.
    Spindler, Karen-Lise G.
    ACTA ONCOLOGICA, 2020, 59 (12) : 1424 - 1429
12345